ArticleJournal of Cancer2021
CD161, a promising Immune Checkpoint, correlates with Patient Prognosis: A Pan-cancer Analysis.
Article in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- KLRB1 gene in tumor immune regulation and disease prognosis: a multidimensional role review.Discover oncology · 2026Review
- Integrative multi-omics analysis identifies C-type lectin CNVs as functional targets for breeding mastitis-resistant dairy goats.Animal microbiome · 2026Article
- Integrative multi-omics characterization of KLRB1/CD161 in diffuse large B-cell lymphoma: associations with immune context, subtype biology, and therapeutic response.Frontiers in molecular biosciences · 2026Article
- Glioma tumor microenvironment and immunotherapy: past, present, and future.Biomarker research · 2025Review
- CD161, a promising prognostic biomarker in hepatocellular carcinoma, correlates with immune infiltration.PeerJ · 2025Article
- Immunobiology roles of the human CD161 receptor in T cells.Frontiers in immunology · 2025Review
- Single-cell RNA-sequencing of human spleens reveals an IDO-1Cancer letters · 2024Article
- Necroptosis-related KLRB1 was a potent tumor suppressor and immunotherapy determinant in breast cancer.Heliyon · 2024Article
- Review
- Screening of Sepsis Biomarkers Based on Bioinformatics Data Analysis.Journal of healthcare engineering · 2022Article
- A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.